Eureka 2019: A New Look at Pituitary Tumors

For the fifth year in a row, Endocrine News spoke with editors from Endocrine Society journals to get the scoop on the top endocrine discoveries of 2019. Here is part 8 of Eureka! 2019.

From April, “DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors,” by Picó, A., et. al. was selected by The Journal of Clinical Endocrinology & Metabolism associate editor Anthony P. Heaney, MD, PhD, professor at the David Geffen School of Medicine at the University of California, in Los Angeles.

“Although pituitary tumors are very common, they are notable for the lack of traditional driver mutations found in other tumor types,” Heaney explains. The team of researchers used PCR to analyze the effect that deoxyribonucleic acid (DNA) methylation would have on expression of 35 tumor suppressor genes (TSGs) in 105 pituitary neuroendocrine tumors (PitNETs). Effects varied with PitNET subtypes.

“This study adds to existing knowledge that epigenetic deregulation, including DNA methylation, histone modification, nucleosome remodeling, and ribonucleic acid (RNA)-mediated targeting, plays a causative role in pituitary tumorigenesis,” Heaney says.

 

You may also like

  • March 2019: Women in Endocrinology

    Gender inequality persists in all sectors of society, including science and medicine disciplines. While female clinicians and researchers are increasing in number[1], they remain underrepresented in scholarly publications and academic positions[2]. Although nearly 50% of medical school graduates are women, they continue to hold fewer senior academic positions and tenured faculty posts than their male…

  • News from ADA 2018

    Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with Canagliflozin Compared to Other Diabetes Medications A new real-world analysis of more than 700,000 U.S. T2D patients found no increased risk of below-knee lower extremity (BKLE) amputation with canagliflozin compared to other sodium glucose…

Find more in